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In the globalisation process, the business of clinical research has 
increased worldwide. While clinical trials have mainly been conducted 
in North America, Western Europe and Australia, the globalisation 
trend has led to a shift to the so-called emerging markets during the 
past two decades.[1] These markets are ‘emerging regions of Eastern 
Europe, Latin America, Asia, the Middle East, and Africa’.[2] While a 
significant increase in clinical trials in emerging countries has been 
observed, there has been a reduction in the proportion of clinical 
trials in North America and Western Europe.[3] Considering the poor 
economic conditions in emerging countries, what makes them so 
interesting for sponsors of clinical trials?
Ten years ago, more than 80% of the clinical trials listed in 
the ClinicalTrials.gov registry were conducted in the developed 
world, while developing countries were under-represented in clinical 
research. Reports now suggest that interest of international sponsors 
in the developing markets is buoyed by several factors associated 
with the profit-orientated business model of the multinational 
pharmaceutical industry[4,5] and by the impact of globalisation, which 
favours export of business to locations where, among other cost-
containment opportunities, labour is cheap, doing business is easy, 
regulatory mechanisms are poor and costs are low. Internationally 
sponsored clinical research is therefore moving to countries where 
the research industry will get the best value for money while gathering 
data acceptable for submission to regulatory agencies.[6] The shift in 
the global clinical trials arena may therefore not necessarily result 
from a primary interest in addressing the local health needs of the 
populations in which the trials are conducted, and there may well 
be a mismatch between local health needs and the research interest 
of the sponsors of the clinical trials. Several past events have given 
credence to these views, including the infamous Pfizer clinical trials 
of Trovan for cerebral meningitis in the naive and poverty-stricken 
population of Tudun Wada, Kano State, Nigeria, which had many 
negative outcomes and for which Pfizer was indicted.[7] This example 
shows that some clinical trials classified as undesirable in developed 
countries can be conducted in developing countries where legal 
requirements are different.[7] In Europe, Pfizer’s licence for Trovan 
was withdrawn owing to several deaths and cases of liver toxicity. In 
Nigeria, however, the clinical trial could be conducted without valid 
approval from an ethics committee.[7]
Nevertheless, the increasing presence of internationally sponsored 
clinical trials in developing countries reflects the fact that these 
countries now ‘represent important growth areas for pharmaceutical 
companies and clinical research organisations’.[6] It also indicates 
growing confidence that the health infrastructure in developing 
countries can reliably match the standards needed to comply with 
the requirements of the International Council for Harmonisation 
of Technical Requirements for Pharmaceuticals for Human Use 
(ICH). [6] There is therefore a need to identify the reasons behind 
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the current interests of sponsors of clinical trials in the developing 
market as a critical step in evaluating how such interests align with 
the health needs of the local population, and whether the ICH 
ethical principles of beneficence and social justice are followed when 
conducting human clinical trials. Certain important questions arise 
that may provide insight into the factors driving the current global 
shift of clinical trials from the North to the South, such as: 
• Can the globalisation trend be observed in the clinical trial arena 
in emerging African markets? This article will examine Nigeria 
and South Africa (SA) specifically.
• Are there possible factors that may influence the clinical research 
business in Nigeria and SA?
• Do most of the drugs being tested in Nigeria and SA address the 
common endemic diseases prevalent in those areas?
• Further insights need to be provided on differences between local 
and international sponsors, both in the number of clinical trials 
and in the indications for these trials.
Objectives
The overall objective of this study was to identify the reasons why 
sponsors increasingly conduct their clinical trials in emerging markets. 
Data on the number of clinical trials in all African countries during the 
period 2010 - 2018 were therefore collected from ClinicalTrials.gov, 
the Pan African Clinical Trials Registry, the National Health Research 
Database and the Nigeria Clinical Trials Registry. We also documented 
whether these studies were financed by national or international 
sponsors, and to what extent diseases related to local medical needs 
were considered. Data extraction was supplemented by data on the 
regulatory framework and the process of and requirements for ethical 
approval of a clinical trial in the selected countries. This was done to 
investigate any possible impact related to the research question.
Methods
Country selection
For appropriate country selection for the research question, it was 
necessary to clarify how emerging countries are defined. For this 
purpose, the Development Assistance Committee (DAC) list of the 
Official Development Assistance recipients of the Organisation for 
Economic Co-operation and Development, effective for reporting on 
2011 flows, was applied.[8] According to this list, emerging countries 
are defined as countries with a lower-middle income of USD1 006 - 
3 975 gross national income per capita in 2010 or an upper-middle 
income of USD3 976 - 12 275. The country selection was limited to 
the African continent because Africa has the highest disease burden 
in the world and a large number of African countries are defined as 
emerging countries in the DAC list and were consequently of specific 
interest to the authors.[9-10]
One country was selected for each of the above income categories. 
SA, an example of an emerging market with an upper-middle income, 
is a country of ~50 million population with the most sophisticated 
and productive economy in sub-Saharan Africa. It has a gross 
domestic product (GDP) of USD368 billion, and has been an active 
player in the clinical trials industry for over four decades.[11,12] In 
contrast, Nigeria, although the largest economy in Africa, is an 
example of an emerging market with a lower-middle income. It has a 
population of nearly 200 million and labour is cheap, yet the economy 
is weak and undiversified, and there is a high disease burden in a 
mostly naive population with extreme variations in level of education. 
Nigeria was not a destination for clinical trials until the current era 
of globalisation.[13,14] The latest re-basing of the economy in 2015 
improved the estimated GDP to nearly USD500 billion, making 
Nigeria the 26th largest economy in the world.[13-15]
Overall, country selection in this study was based on availability of 
data on the research questions and the connection to local research 
partners.
A search of clinical trial databases
To provide a comprehensive overview of clinical trials ever conducted 
or ongoing in African countries, a corresponding database query 
was conducted in the ClinicalTrials.gov registry of the US National 
Library of Medicine at the National Institutes of Health[16] as well 
as in the Pan African Clinical Trials Registry.[17] Subsequently, trend 
data from ClinicalTrials.gov were determined covering the period 
2010 - 2018 for the selected countries, SA and Nigeria. In parallel, the 
National Health Research Database of the SA National Department 
of Health (NDoH)[18] and the Nigeria Clinical Trials Registry of the 
Federal Ministry of Health[19] were also used to obtain trend data. 
From information on ClinicalTrials.gov, the indication area and the 
sponsor type (local or international) were determined. A distinction 
was made between the two financing types, i.e. international or 
national sponsors.
Health statistics of the World Health Organization  
and local regulatory and ethical guidelines
Health data for 2013 and 2015 on the selected countries, SA and 
Nigeria, were extracted from the 2016 fact sheets of health statistics 
of the World Health Organization (WHO).[20,21] Similarly, 2012 
disease incidence and prevalence rates were used for this research 
and served as the starting point for investigation of the extent to 
which clinical trials were able to meet indications with a particular 
local medical significance. The data extraction was supplemented by 
data on the regulatory framework and the process and requirements 
for ethical approval of a clinical trial in both selected countries. This 
was considered necessary to investigate any possible impact related 
to the research question. The South African Good Clinical Practice 
Guidelines of the NDoH[22] as well as the SA ClinRegs website of the 
National Institute of Allergy and Infectious Diseases of the National 
Institute of Health[23] and the Guidelines for Clinical Trial Application 
in Nigeria of the National Agency for Food and Drug Administration 
and Control (NAFDAC) in Nigeria[24] were used to compare the 
framework conditions of the national authorities. In addition to 
analysing the legal framework for the national authorities, the ethical 
frameworks of the national ethics committees were compared. 
The document Ethics in Health Research – Principles, Processes and 
Structures of the NDoH in SA[25] and the National Code of Health 
Research Ethics of the Federal Ministry of Health in Nigeria[26] were 
used as source documents.
Data analysis
Data collected on sponsorship were used to investigate whether there 
were differences between local and international sponsors, both in 
the number of clinical trials and in the indication areas. Available 
data from Nigeria and SA were analysed and characterised separately 
using SPSS software version 26 (IBM, USA). The outcome of interest 
was the number of clinical trials related to indication areas. The data 
were evaluated using descriptive statistics and trend analysis.
Results
Search results
The ranking of all African countries according to the number of all 
registered clinical trials in ClinicalTrials.gov (Table 1) up to 2018 
shows that SA, with a total of 2 545 registered trials, was the country 
with the second-highest number of trials on the African continent 
after Egypt, while Nigeria was ranked 10th, with 145 registered 
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clinical trials. In comparison, the ranking of all African countries 
that have registered clinical trials in the Pan African Clinical Trials 
Registry up to 2018 shows that Egypt, with a total of 886 clinical 
trials, and SA, with 193, were the two countries with the highest 
number of registered clinical trials, but Nigeria ranked third with 
a total of 172 registered clinical trials. The number of clinical trials 
registered in Nigeria as shown in the continental Pan African 
Clinical Trials Registry is higher than in the more widespread 
ClinicalTrials.gov registry. Since Nigeria is the only country with a 
disparity in its position on the two clinical trials registries, and given 
that comparison of the results of the two registries indicates that 
a larger number of clinical trials are registered in the well-known 
ClinicalTrials.gov registry, only the ClinicalTrials.gov registry was 
used for further data analysis in this study.
Review of the number of clinical trials registered in the National 
Health Research Database in SA between 2010 and 2018 identified a 
total of 5 374 registered clinical trials. Its Nigerian counterpart, the 
Nigeria Clinical Trials Registry, works only as a tool for submitting 
registrations to the Pan African Clinical Trials Registry and processes 
the comparatively low 172 trial registrations recorded there. Nigeria 
therefore does not have a specific database for clinical trials, and 
the National Health Research Database in SA is unable to cover the 
entire research period from 2010 to 2018, as the database has only 
been archived since 2013. As the two databases were not established 
and do not operate according to similar standards, no meaningful 
comparison of the data is possible, and only the ClinicalTrials.gov 
registry was therefore included in the final data analysis.
Globalisation and trends in clinical trials in Nigeria 
and SA
The trend lines in Fig. 1 show that Nigeria recorded a relative 
increase in the number of clinical trials from 2010 to 2018. In 
contrast, SA has been in a clear downward trend in the number of 
clinical trials started annually since 2010, even if absolute numbers 
are still four times higher than in Nigeria.
Factors that may influence the clinical trials business in 
Nigeria and SA
In identifying possible factors that might influence the clinical 
research business in Nigeria, various health data including 
demographic statistics were selected and compared with those in 
SA (Supplementary Table 1, available at http://samj.org.za/public/
sup/14870-t.pdf). Key differences in some factors were observed 
that may differently impact on the clinical trials business in the 
two countries, including population demographics, country-specific 
diseases, socioeconomic variables, and the nature of the regulatory 
framework/laws governing clinical trials, especially the time required 
to obtain approval for a clinical trial application. It is striking that 
Nigeria has three times as many inhabitants as SA, and that average 
life expectancy is 8 years shorter than that in SA. Nigeria also has a 
significantly higher proportion of children, and the mortality rate 
in children aged <5 years is nearly three times as high as that in SA. 
The number of women who die during pregnancy or childbirth is 
also significantly higher in Nigeria than in SA, with 814 v. 138 deaths 
per 100 000 live births. The frequent occurrence of specific diseases 
also plays a role here. In this context, malaria and leprosy have been 
identified as country-specific diseases in Nigeria, while SA has high 
incidences of HIV/AIDS and tuberculosis (TB) (Table 2). It could 
therefore be assumed that these diseases would be particularly 
frequently investigated in clinical studies, considering the availability 
of a large patient pool that means a fast recruitment process for any 
given study, which saves time, is cost-effective and suits the profit-
orientated business models of national and international sponsors. 
The less stringent regulatory laws in Nigeria, including the shorter 
time required to obtain approval for a clinical trials application, 
would also save time and reduce the cost of business. This factor may 
explain the current shift of international sponsors to Nigeria rather 
than SA under the globalisation process.
Matching drug development research studies to the 
locally endemic diseases
The list of the 10 fields of study most often researched in Nigeria 
and SA between 2010 and 2018 (Table 3) shows that communicable 
diseases and infections were most frequently researched in both 
countries. Similarly, clinical trials on HIV/AIDS were increasingly 
conducted in both countries. HIV/AIDS is one of SA’s country-specific 
diseases, so it is not surprising that HIV/AIDS is a popular study area 
there. Surprisingly, TB, the second most common disease in SA, is not 
listed among the top 10 study areas in that country. In Nigeria, malaria 
is the only country-specific disease that is listed among the top 10 study 
areas, and leprosy is not included separately on the list.
Assessing differences between local and international 
sponsors, both in number of clinical trials and 
indication areas
A subsequent distinction was made between national and 
international sponsorship of clinical studies in the two countries. 
National sponsors were operationalised to include universities and 
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Fig. 1. Trends in clinical trials associated with globalisation. The solid lines represent the real development course according to the data sets, and the dotted 
lines help to visualise the upward or downward trend between the starting point and the endpoint of the research time period.
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hospitals, individuals, organisations and industries that are locally 
based in the country and conduct clinical trials (Supplementary 
Table  2, http://samj.org.za/public/sup/14870-t.pdf). International 
sponsors, as previously mentioned, are located outside the country 
where they conduct clinical trials, and include such agencies as 
the National Institutes of Health and other US federal agencies 
(Supplementary Table 3, http://samj.org.za/public/sup/14870-t.pdf). 
Supplementary Table 2 shows the number of clinical trials funded 
by national sponsors between 2010 and 2018, while Supplementary 
Table 3 shows the number funded by international sponsors. In 
SA, the number of clinical trials funded by national sponsors 
generally increased between 2010 and 2018, while the number of 
internationally funded trials decreased during this time (Fig. 2). 
In Nigeria, however, the number of both nationally funded and 
internationally funded clinical trials increased (Fig. 3).
Sorting of the clinical trials into the country-specific diseases listed 
in the WHO fact sheets indicates that in SA, HIV/AIDS and TB are 
studied in both nationally and internationally funded trials, whereas 
in Nigeria, malaria is the only country-specific disease investigated 
by nationally and internationally funded studies. It was also observed 
that in Nigeria, national and international sponsors are focusing on 
studies on HIV/AIDS instead of leprosy.
It was considered reasonable that country-specific diseases should 
not be considered the only possible basis for an increased number of 
studies in the two emerging countries, Nigeria and SA. Other factors, 
such as differences between the regulatory framework of national 
authorities (Supplementary Table 4, http://samj.org.za/public/
sup/14870-t.pdf) and ethics committees (Supplementary Table 5, 
http://samj.org.za/public/sup/14870-t.pdf) of the two countries, 
should count as well. Based on the analysis, it is striking that the South 
African Health Products Regulatory Authority (SAHPRA) and/or 
the Medicines Control Council (MCC), as the national regulatory 
authority in SA, take an average of 60 - 80 working days to approve 
a clinical trial application. NAFDAC, Nigeria’s national regulatory 
authority, takes 60 working days to approve a clinical trial application, 
although this may be longer in some cases. A further advantage for 
Nigeria could be the possibility of a scientific advice meeting and 
provision for personal presentation of the study to NAFDAC by the 
sponsors. This service is not offered by SAHPRA and/or the MCC in 
SA. Comparison of the ethical framework conditions of the National 
Health Research Ethics Council in SA and the National Health 
Research Ethics Committee in Nigeria shows that both countries have 
very similar ethical framework conditions except for shorter approval 
time for a clinical trial application of an average of 20 - 40 working 
days in SA compared with 60 working days in Nigeria.
Discussion
Comparison of the number of registered clinical trials in the 
ClinicalTrials.gov registry, maintained by the US National Library of 
Medicine, and the continental Pan African Clinical Trials Registry 
shows that trial registration is more frequent in ClinicalTrials.gov. It 
can therefore be assumed that many clinical trials by international 
pharmaceutical companies are not additionally registered in local 
national trial registries. From an ethical point of view, this could 
pose a hurdle for clinical trial participants, as the responsible 
pharmaceutical industry expects every participant to be familiar 
with the ClinicalTrials.gov registry and its functionality. In terms 
of user-friendliness and time efficiency, it would certainly be more 
convenient for participants in some developing countries to obtain 
all trial information in their own language from a national trial 
registry. Consequently, it would be ethically ambitious to force 
international pharmaceutical industries to additionally register their 
clinical trials in a national study registry if such exists. In this 
context, the increase in the local number of trial registrations in the 
Table 1. Ranking of African countries according to the 
number of registered clinical trials in ClinicalTrials.gov
Country Clinical trials, n
Egypt 2 620









Table 2. Comparison of country-specific diseases in Nigeria 





Tuberculosis 108 1 003
Malaria 28 710 33
Neglected tropical diseases  
(new cases of leprosy)
3 805 15
Table 3. Top 10 fields of study researched in South Africa and Nigeria
South Africa Registered studies, n Nigeria Registered studies, n
Communicable diseases 348 Communicable diseases 33
Infections 348 Infections 33
Immune system diseases 319 AIDS 22
AIDS 268 HIV infection 22
HIV infection 268 Malaria 15
Respiratory tract diseases 209 Parasitic diseases 14
Metabolic diseases 186 Protozoan infections 14
Viral diseases 175 Viral diseases 14
Lung diseases 169 Haematological diseases 12
Syndrome 159 Anaemia 11
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National Health Research Database from 2013 to 2018 is striking, 
as is the simultaneous decrease in registrations in the ClinicalTrials.
gov registry. These changes could signify a shift from internationally 
managed trial registries to nationally managed registries.
According to Glickman et al.[27] (2009), ‘clinical trials increasingly 
occur on a global scale as industry and government sponsors in 
wealthy countries move trials to less wealthy countries. This trend 
suggests that clinical research is undergoing the same globalisation 
process as other industries.’ However, this process may not be the 
same for every emerging market. Fig. 1 shows that the assumed 
upward trend in SA has even turned into a downward trend in the 
last 8 years. So the globalisation trend in favour of the SA market is 
already over, and the country seems to have become less attractive 
for clinical trials despite its high clinical trial numbers. Even with this 
obvious downward trend, SA is still in second place in the ranking 
of African countries according to the number of registered clinical 
trials. On this basis, it may be speculated that SA is regarded as the 
country on the African continent that has made the most progress 
in its development and is most aligned with Western industrialised 
countries in some areas, so that appropriate medical care and 
sufficiently developed infrastructures are available to conduct clinical 
trials. This alignment with the Western industrialised countries could 
have been developed in the past years through some tightening of 
the regulatory laws governing the conduct of clinical trials in SA. 
SA’s former advantage as a lesser-regulated clinical trial arena has 
therefore gradually turned into a disadvantage, in that the regulatory 
framework for conducting clinical trials is so aligned with those of 
the Western world that initiating a trial in SA is now just as time-
consuming, and therefore also as costly, as in the Western countries. 
The consequences of the westernised regulatory framework are also 
supported by an average approval time for a clinical trial application 
of 60 - 80 working days in SA, which may be one of several reasons 
for the decline in the number of clinical trials in SA.
A decline in the clinical trials trend in SA is more obvious when 
considering the number of registered studies on its country-specific 
diseases, HIV/AIDS and TB. The trend line diagrams show that 
clinical studies on HIV/AIDS and TB in SA are financed by national 
sponsors on the one hand, and international sponsors on the other. 
Given that the number of HIV/AIDS clinical trials in SA has been 
declining since 2015, unlike Nigeria, it is reasonable to infer that 
Nigeria is more attractive for the clinical research business. This view 
is plausible even though the country still ranks 10th among African 
countries in the number of registered clinical trials. This anomaly 
could be related to the fact that the clinical research business in 
Nigeria is still in its early stages of development. The regulatory 
and ethical frameworks necessary for the successful conduct of 
clinical trials have therefore only recently been adapted to the 
globally applicable Good Clinical Practice guidelines to abolish the 
‘bureaucratic, politically-influenced and lacking-in-transparency’ 
review processes of research projects, which as Petros[28] said, had 







































































2010  2011  2012  2013  2014  2015  2016  2017  2018
Year
2010  2011  2012  2013  2014  2015  2016  2017  2018
Year
2010  2011  2012  2013  2014  2015  2016  2017  2018
Year














































Fig. 2. National v. international sponsorship in South Africa. The solid lines represent the real development course according to the data sets, and the dotted 
lines help to visualise the upward or downward trend between the starting point and the endpoint of the research time period.
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Fig. 3. National v. international sponsorship in Nigeria. The solid lines represent the real development course according to the data sets, and the dotted lines 
help to visualise the upward or downward trend between the starting point and the endpoint of the research time period.
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previously been practised. For this purpose, the Association for Good 
Clinical Practice (AGCPN) in Nigeria was founded in 2005, which 
aimed to make Nigeria more attractive for conducting clinical trials. 
In 2012, the AGCPN held its first clinical trial summit to identify gaps 
in the clinical research industry in Nigeria and offer tailored strategic 
solutions, which have included lobbying governmental agencies 
to restructure their approach to clinical research.[29] These positive 
efforts have affected the national regulatory authority – NAFDAC – 
and the National Health Research Ethics Committee, which have set 
themselves a time limit of a maximum of 60 working days for the 
approval of a clinical trial application. Since the sponsor of a clinical 
trial can save a lot of time and money through these options, Nigeria 
appears to have become more attractive for sponsors than SA. All 
these beneficial regulatory changes could explain why Glickman et 
al.[27] also hold the view that ‘companies can realise substantial cost 
savings by conducting trials’ in emerging countries. An increasing 
medical need for research on the various country-specific diseases 
that occur most frequently could be another possible reason for 
the growing attractiveness of emerging markets for conducting 
clinical trials. A direct comparison shows that in SA, both local and 
international sponsors are interested in researching country-specific 
diseases, except for TB, even if international interest does not seem 
to be as strong as expected. In Nigeria, the second-highest country-
specific disease, leprosy, has not attracted the interest of sponsors. 
Instead, a few HIV/AIDS studies have been conducted by national 
and international sponsors. Invariably, in conducting clinical research 
in the emerging markets, both national and international sponsors do 
not seem to prioritise the more prevalent country-specific diseases. 
This failure could be an indication that the underlying interests for 
most of the clinical studies in emerging countries are not related to 
the prevalent local health needs, but reflect the business priorities of 
the international sponsors. It could also be assumed that the research 
companies are more interested in non-communicable diseases, which 
could be regarded as international diseases. However, the overall 
rise in the number of studies done in Nigeria could indicate that the 
clinical research business has only just begun.
It was revealed that the number of HIV/AIDS studies in Nigeria 
has risen significantly since 2015. However, if one considers the 
decreasing trend in SA’s return of HIV/AIDS-related clinical trials 
since 2015, with increasing numbers of such trials reported in 
Nigeria, the emerging picture suggests a shift in HIV/AIDS studies 
from SA to Nigeria. Since SA has the largest HIV epidemic in the 
world, with 19% of the global number of people living with HIV, 15% 
of new infections and 11% of AIDS-related deaths, it is not surprising 
that ‘South Africa has the largest treatment programmes in the world’ 
and ‘also has one of the largest domestically funded programmes, 
with about 80% of the AIDS response funded by the government’. [30] 
Awareness-raising work on HIV/AIDS in SA, through campaigns 
such as that of UNAIDS (the Joint United Nations Programme on 
HIV and AIDS), has brought the disease to people’s notice and may 
be playing an important role in the substantial attention given to 
research on HIV/AIDS as a country-specific disease. The medical 
care of patients would have helped to contain the disease as well 
as to inform about possible ways of infection, and explore novel 
treatment options through clinical research studies. In Nigeria, on 
the other hand, medical care and awareness-raising efforts seem not 
to be as robust as in SA. The facts from the health data comparison 
suggest that healthcare in Nigeria has deteriorated considerably, 
as indicated by the shorter life expectancy and higher maternal 
and under-5 mortality rates compared with SA. Since the Nigerian 
population is three times larger than that of SA, and in addition 
to the lack of quality healthcare a sizeable baby boom prevails, it is 
even more difficult to implement awareness campaigns such as those 
of UNAIDS, which has also started its work in Nigeria. Given the 
observed scenario, it is plausible that either the Nigerian population 
is not yet enlightened enough to know that use of condoms can not 
only decrease the birth rate but also minimise infection with HIV/
AIDS, or there are other factors, such as religious beliefs, that hinder 
successful awareness raising. Nevertheless, since Nigeria has the 
second-largest HIV epidemic globally, it is not surprising that the 
patient pool there is large enough to conduct clinical trials on HIV/
AIDS.[31] Miller et al.[32] explain quite rightly that ‘research should 
be responsive to the health needs of communities’. If, however, the 
medical needs should reflect the country-specific diseases mentioned 
in the fact sheets of the WHO, it is astonishing that in both SA and 
Nigeria only one of the country-specific diseases is included in the 
list of the top 10 study areas. However, this list also shows that most 
clinical trials were conducted in the field of communicable diseases in 
Nigeria and SA. Since the not explicitly mentioned country-specific 
diseases TB and leprosy (which belongs to the neglected tropical 
diseases) fall under the generic term communicable diseases, they are 
probably also the subject of clinical trials in the respective countries.
In addition to the growing medical need for research on country-
specific diseases, increasing capacity building may also be required in 
both countries. This does not only mean the building of medical care 
centres, such as hospitals, but also the fundamental improvement 
of medical care. The conduct of internationally sponsored clinical 
trials creates attractive opportunities that keep medical experts in 
the country, and according to Ali and Finlayson,[33] also provides 
them with regular training opportunities that expand their medical 
expertise. This again benefits the population to be cared for. The 
term capacity building, in the business of clinical research, therefore 
covers several aspects and is also of importance for the development 
of clinical research in developing countries.
Study limitations
The following limitations of this study should be taken into account. 
Firstly, updated incidence rates were published in the WHO 2018 
fact sheets after this article was completed. Secondly, only the 
internationally recognised database ClinicalTrials.gov for the 
registration of clinical trials was used to process the research 
question, whereas there are other local databases such as the National 
Health Research Database in SA, apart from the Pan African Clinical 
Trials Registry. These un-utilised databases may provide additional 
information on the trends in the business of clinical research in 
Nigeria and SA, but were not included in this study for reasons 
mentioned in the ‘Methods’ section.
Conclusions
Implications for practice
The findings of this study demonstrate that globalisation has an 
impact on the clinical trials arena in the emerging countries, especially 
Nigeria and SA. The findings indicate that there are several reasons 
why sponsors are increasingly having their clinical trials conducted in 
emerging markets such as SA and Nigeria. These reasons include an 
increased medical need for research into the various country-specific 
diseases that, owing to their high incidence rates, have a large pool 
of naive patient groups. This makes fast recruitment possible and 
translates to cost savings due to time saved. In Nigeria, the shortened 
processing time for the evaluation of a clinical trial application adds 
to the country’s attractiveness as a profitable market for conducting 
clinical research compared with SA. It also explains why there has 
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been a downward trend in the number of registered clinical trials in 
SA from 2010 to 2018 but an upward trend in the number in Nigeria. 
This finding is reinforced by the observation that while the number 
of local sponsors increased in SA, the number of international 
sponsors decreased over the same period. In contrast, both local and 
international sponsors increased in Nigeria. Other reasons, according 
to Clinical Research South Africa,[34] include qualitative data provided 
quickly and affordably by qualified researchers, and the presence 
of genetically diverse population groups in a country. In emerging 
markets, a lower drop-out rate of clinical trial participants is also 
expected, as participation in a clinical trial is often the only option 
for good medical care. Nevertheless, the increasingly tight regulatory 
environment in SA makes it similar to the Western world, and for this 
reason sponsors will look more favourably towards Nigeria than SA 
when conducting clinical trials.
Implications for research
Further research relating to the annual trends in the number of 
registered clinical trials in the SA local database (the National Health 
Research Database) should be done to determine whether the local 
database, apart from the Pan African Clinical Trials Registry, reflects 
a similar trend in the business of clinical research to that reported in 
this study. SA may well be used as a case study in a further analysis 
to find out whether the number of trial registrations has increased 
annually between 2013 and 2018, and whether the introduction of the 
National Health Research Database has led to a shift of registrations 
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